Mhgc. Kranenborg et al., THE EFFECT OF ANTIBODY PROTEIN DOSE OF ANTIRENAL CELL-CARCINOMA MONOCLONAL-ANTIBODIES IN NUDE-MICE WITH RENAL-CELL CARCINOMA XENOGRAFTS, Cancer, 80(12), 1997, pp. 2390-2397
BACKGROUND. Antibodies preferentially can direct radionuclides to soli
d tumors. However, antibody uptake in tumors is often highly heterogen
eous. This heterogeneity may be overcome by increasing antibody protei
n dose. METHODS. The biodistribution of increasing protein doses of ra
dioiodinated antirenal cell carcinoma (RCC) monoclonal antibodies (MoA
bs) G250 and RC 38 was studied in mice with NU-12 or SK-RC-52 RCC xeno
grafts. In addition, MoAb affinity constants and antigen densities (Sc
atchard analysis) and MoAb processing (internalization) were determine
d in vitro. RESULTS. The relative uptake of G250 in NU-12 tumors was v
ery high at low protein doses (125% injected dose/g [%ID/g]), but decr
eased at higher doses, suggesting tumor saturation. Indeed, saturation
of G250 antigen occurred at 3 mu g protein. In this model, 9200 G250
determinants per NU-12 cell could be targeted, which is only 6.1% of t
he 150,000 G250 determinants per NU-12 cell as determined in vitro. Th
e RC 38 uptake in NU-12 tumors remained constant up to the 10 mu g dos
e level (40% ID/g) and decreased at higher doses. RC 38 antigens were
saturated at 25 mu g of RC 38. With RC 38, 15% of the available RC 38
antigens per NU-12 tumor cell were targeted. In contrast, G250 uptake
in SK-RC-52 tumors was very low at low antibody dose (4% ID/g at 1 mu
g) and increased with increasing protein dose. These differences in G2
50 biodistribution might be related to differences in the processing o
f G250 by the tumor cells. CONCLUSIONS. Our studies show that some RCC
tumors can be saturated with anti-RCC MoAbs at low (25 mu g) to very
low (3 mu g) protein doses. At nonsaturated doses relatively high tumo
r uptake can be achieved. Surprisingly in NU-12 tumors only 6.1% and 1
5% of the available antigenic sites were targeted at the saturating do
se levels with G250 and RC 38, respectively. (C) 1997 American Cancer
Society.